Latest automation and digitization technology for the production of Covid 19 vaccines

BioN­Tech SE, a biotech­nol­o­gy com­pa­ny based in Mainz, Ger­many, and Siemens plan to expand their strate­gic coop­er­a­tion. The com­pa­nies intend to inten­si­fy their coop­er­a­tion in the rapid expan­sion and devel­op­ment of pro­duc­tion for the Covid 19 vac­cine. BioN­Tech had announced its inten­tion to build new Covid 19 vac­cine pro­duc­tion facil­i­ties world­wide, includ­ing a pro­duc­tion facil­i­ty in Sin­ga­pore, based on the Mar­burg plant and its technology.

In Mar­burg, the phar­ma­ceu­ti­cal com­pa­ny had con­vert­ed an exist­ing plant for the pro­duc­tion of the vac­cine in five months with the help of Siemens. As part of the col­lab­o­ra­tion, Siemens will con­tribute the lat­est automa­tion and dig­i­ti­za­tion tech­nolo­gies for BioN­Tech’s pro­duc­tion facil­i­ties, includ­ing design, sim­u­la­tion and engi­neer­ing soft­ware as well as process con­trol technology.

“Siemens and BioN­Tech have been work­ing togeth­er suc­cess­ful­ly for a long time.  It was the first com­pa­ny to launch a new mRNA vac­cine togeth­er with Pfiz­er. Our tech­nolo­gies and years of expe­ri­ence helped them turn around pro­duc­tion in five months instead of a year. Now we want to trans­fer this suc­cess to oth­er man­u­fac­tur­ing sites togeth­er — mak­ing the Covid 19 vac­cine avail­able world­wide as quick­ly as possible.”

- Cedrik Neike, Mem­ber of the Man­ag­ing Board of Siemens AG and CEO Dig­i­tal Industries